Roles
- Associate Professor of Clinical Medicine
-
Biography
Juan Alderuccio, M.D., is an Associate Professor of Clinical Medicine in the Division of Hematology at the University of Miami Miller School of Medicine. He specializes in the study and treatment of patients with lymphoma, with primary research that seeks to design and conduct clinical trials that combine agents associated with higher efficacy and lower toxicity in difficult-to-treat B-cell lymphomas. -
Education & Training
Education
Post Graduate Training
-
Honors & Awards
-
Research Interests
My research concentrates in experimental therapeutics, deployment of machine learning tools in molecular imaging, and development of PET/CT-based biomarkers in lymphoma. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Clinical Trials
Viewing 0 of 10 clinical trials.
-
To determine the safety and tolerability of a new study drug, TORL-5-700, on its own or in combination with other treatments that may be effective against your disease.
- Principal Investigator: Juan Alderuccio
- Study Phase: Phase I/II
- Enrollment Status: Open
-
A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
- Principal Investigator: Juan Alderuccio
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
- Principal Investigator: Juan Alderuccio
- Study Phase: Phase 2
- Enrollment Status: Open
-
This research study is evaluating the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a possible treatment for this diagnosis.
- Principal Investigator: Juan Alderuccio
- Study Phase: Phase II
- Enrollment Status: Not Accepting
-
The purpose of this study is to evaluate if the investigational combination of loncastuximab tesirine in combination with another anti-cancer agent is a safe and effective treatment for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma.
- Principal Investigator: Juan Alderuccio
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
A research study to find out if PIT565 is safe and can help people like you who have Non-Hodgkin lymphoma or acute lymphoblastic leukemia disease and who have relapsed (cancer return after a period of improvement) and/or are refractory (cancer remains and does not respond to treatment).
- Principal Investigator: Juan Alderuccio
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
Determine the recommended Phase 2 dose schedule of Pola-R-CHP in combination with HD MTX and Zanubrutinib (MRZ-Pola-CHP) in patients with SCNSL.
- Principal Investigator: Juan Alderuccio
- Study Phase: Phase I
- Enrollment Status: Open
-
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
- Principal Investigator: Juan Alderuccio
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements
- Principal Investigator: Juan Alderuccio
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Closed
-
To evaluate the safety profile and tolerability of epcoritamab withloncastuximab
- Principal Investigator: Juan Alderuccio
- Study Phase: Phase II
- Enrollment Status: Open